Theory Paper IIDrNB Cardiology – Theory Notes
CARDIAC SARCOIDOSIS: CLINICAL FEATURES, DIAGNOSIS, AND MANAGEMENT
IDEFINITION AND DUAL-PHASE PATHOPHYSIOLOGY
- Definition (HRS 2014 / AHA 2024 / ESC 2023): Cardiac Sarcoidosis (CS) is a multisystem granulomatous inflammatory disorder of unknown etiology characterized by the infiltration of compact, non-caseating (non-necrotizing) epithelioid granulomas (composed of activated macrophages, multinucleated giant cells, and CD4+ Th1/Th17 lymphocytes) primarily within the myocardium, interventricular septum, and conduction system.Clinically manifest in 5 percent of patients with systemic sarcoidosis, but present on autopsy or advanced imaging in 25 to 30 percent, with up to 25 percent presenting as clinically isolated cardiac sarcoidosis.
- Two Distinct Pathological Phases (Dictating Dual-Track Therapy):
- Active Granulomatous Inflammatory Phase: Focal granulomas and surrounding myocardial edema compress and interrupt the His-Purkinje system and trigger abnormal automaticity or triggered activity, causing potentially reversible high-grade AV block, polymorphic ventricular arrhythmias, and acute LV/RV dysfunction (targeted by Immunosuppression).
- Chronic Post-Inflammatory Fibrotic (Scar) Phase: Healing via TGF-beta and fibroblast activation replaces myocardium with dense, patchy collagen scar and ventricular aneurysms, creating fixed anatomical slow-conduction channels that sustain re-entrant Monomorphic Ventricular Tachycardia (MMVT) and chronic heart failure (targeted by ICD Implantation and Catheter Ablation).
IICLINICAL FEATURES (THE CLASSIC TRIAD)
- Conduction System Abnormalities (Most Common Initial Presentation — 30 to 45 Percent):
- Hallmark: Complete (3rd-degree) or Mobitz Type II 2nd-degree Atrioventricular (AV) Block, or new Right Bundle Branch Block / fascicular block, resulting from granulomatous infiltration of the basal interventricular septum.
- Clinical Red Flag: Idiopathic high-grade AV block in any young or middle-aged adult (<60 years of age) is due to occult Cardiac Sarcoidosis in 15 to 30 percent of cases and mandates pre-pacemaker CMR and/or 18F-FDG PET screening.
- Ventricular Tachyarrhythmias and Sudden Cardiac Death (SCD — ~30 Percent): Frequent complex PVCs, non-sustained VT, sustained monomorphic or polymorphic VT, or Sudden Cardiac Death (which accounts for 30 to 65 percent of all deaths in CS and can be the very first presentation).
- Heart Failure and Cardiomyopathy Phenotypes (20 to 30 Percent): Most commonly mimics Dilated Cardiomyopathy (DCM) with regional wall motion abnormalities, or presents as Restrictive Cardiomyopathy, Right Ventricular failure mimicking ARVC, or ventricular aneurysms. (Atrial arrhythmias occur in 20 to 30 percent due to atrial granulomas or LA dilation.)
IIIMULTIMODALITY DIAGNOSTIC ALGORITHM (HRS 2014 / JCS 2016 / AHA 2024)
- Transthoracic Echocardiography (Screening Tool — Low Sensitivity in Early Disease):
- Pathognomonic Hallmark: Thinning and akinesia/aneurysm of the basal anterior/inferior interventricular septum (wall thickness <4 mm) or regional wall motion abnormalities in a non-coronary distribution, or focal basal septal thickening (>13 mm) during acute granulomatous edema, plus impaired Global Longitudinal Strain (GLS).
- Cardiac Magnetic Resonance (CMR — Class I Anatomical Scar Reference):
- Hallmark: Patchy, multifocal Late Gadolinium Enhancement (LGE) most commonly in the basal interventricular septum (often extending across the septum into both RV and LV free walls — the pathognomonic “Hook Sign”) and subepicardial/mid-myocardial basal inferolateral wall (sparing the subendocardium, though transmural LGE occurs in advanced scars).
- Prognostic Value: Presence and extent of LGE (especially LGE >10 to 20 percent of LV mass or any RV LGE) is the single strongest independent predictor of VT and Sudden Cardiac Death, even when LVEF is completely normal (>50 percent).
- Cardiac 18F-FDG PET/CT + Perfusion Imaging (Class I Metabolic Inflammation Reference):
- Mandatory Preparation: 24-to-48-hour high-fat, zero-carbohydrate diet + 12-to-18-hour fast (+ IV unfractionated heparin 50 IU/kg) to suppress physiological cardiomyocyte glucose uptake.
- Hallmark: Focal or focal-on-diffuse myocardial 18F-FDG uptake colocalized with a resting Rb-82 / N-13 ammonia perfusion defect (“Perfusion-Metabolism Mismatch”), alongside FDG-avid bilateral hilar or mediastinal lymphadenopathy (which provides a high-yield target for EBUS-guided biopsy).
- Histological Confirmation (Extracardiac Biopsy vs. Guided Endomyocardial Biopsy):
- HRS 2014 Pathways: Diagnosis is established either by (A) Direct Endomyocardial Biopsy (EMB) showing non-caseating granulomas (note: blind RV apical EMB has a sensitivity of only 20 to 25 percent due to patchy basal/LV distribution, which doubles to ~50 percent when guided by intra-procedural 3D Electroanatomical Voltage Mapping targeting fractionated low-voltage border zones [1.5–0.5 mV] or PET/CMR imaging), OR (B) Clinical Pathway: Histological proof of extracardiac sarcoidosis (via EBUS mediastinal node, lung, or skin biopsy) plus compatible cardiac imaging (CMR LGE or PET uptake) and clinical features (AV block, VT, or steroid-responsive cardiomyopathy).
| Diagnostic / Therapeutic Domain | Primary Modality / Intervention | Specific Guideline Criterion / Action (HRS 2014 / ESC 2022 / AHA 2024) |
|---|---|---|
| Active Myocardial Inflammation | Cardiac 18F-FDG PET/CT (with high-fat/fasting prep) | Dictates Immunosuppression (Class I/IIa): Prednisone (0.5 mg/kg/d or 30–40 mg/d) + early Methotrexate (repeat PET at 3–6 mo to guide taper) |
| Arrhythmogenic Fibrotic Scar | Cardiac MRI with LGE | Dictates Sudden Death Protection (ICD): High SCD risk persists even after PET inflammation resolves (ILLUMINATE-CS) |
| ICD Class I Indications | Secondary prevention or severe HFrEF | (1) Sustained VT or Aborted Cardiac Arrest; OR (2) LVEF <= 35% despite optimal medical therapy and immunosuppression |
| ICD Class IIa Indications (The “Low-Threshold” Rules) | Primary prevention with LVEF >35% | (1) ANY indication for permanent pacing (e.g., high-grade/Complete AV Block) -> implant ICD instead of pacemaker regardless of LVEF; (2) Significant LGE on CMR (ESC 2022 / ACC-AHA 2017); (3) Unexplained syncope; or (4) Inducible sustained VT on EPS (LVEF 36–49% and/or RVEF <40% alone is IIb in HRS 2014) |
IVGUIDELINE-DIRECTED MANAGEMENT (IMMUNOSUPPRESSION, DEVICES, AND ABLATION)
- Immunosuppressive Therapy (Indicated for Active FDG-PET Inflammation + AV Block, VT/PVCs, or LV/RV Dysfunction):
- First-Line Corticosteroids (Class I / IIa): Oral Prednisone / Prednisolone at 0.5 mg/kg/day (typically 30 to 40 mg/day) (contemporary practice favours 30 to 40 mg/day over historical 60 mg/day dosing to limit weight gain and diabetes; the randomized CHASM-CS-RCT is still enrolling). Reverses Mobitz II / complete AV block in ~40 to 50 percent of patients (versus 0 percent spontaneous recovery in untreated CS) and preserves LVEF.
- Early Steroid-Sparing Second-Line Agents (Class IIa): Methotrexate (10 to 20 mg once weekly + folic acid) (preferred first-line steroid sparer), Mycophenolate Mofetil, Azathioprine, or Leflunomide initiated upfront or early to enable steroid tapering over 6 to 12 months and prevent relapse (which occurs in 30 to 40% upon stopping steroids alone).
- Third-Line Biologics for Refractory CS: TNF-Alpha Inhibitors — Infliximab (5 mg/kg IV at Weeks 0, 2, 6, then every 4–8 weeks) or Adalimumab are effective in steroid/methotrexate-refractory active disease (after strictly excluding latent/active Tuberculosis and adjusting for severe NYHA IV heart failure).
- Serial FDG-PET Monitoring: Repeat Cardiac 18F-FDG PET at 3 to 6 months after starting therapy to confirm metabolic resolution before tapering corticosteroids.
- Antiarrhythmic Drugs and Catheter Ablation:
- Medical Suppression: Amiodarone or Sotalol (plus Beta-blockers) are used for recurrent VT; Class IC Sodium Channel Blockers (Flecainide, Propafenone) are strictly contraindicated (Class III) due to myocardial scar and proarrhythmia.
- Catheter Ablation (Class IIa for Refractory VT): Performed only after active myocardial inflammation has been suppressed with immunosuppression (ablating acutely edematous, inflamed myocardium has high failure and recurrence rates) and frequently requires combined endocardial and percutaneous epicardial mapping/ablation due to deep intramural/subepicardial RV and LV scars.
VLANDMARK REGISTRIES AND CLINICAL TRIALS
- ILLUMINATE-CS Registry (Nabeta et al., Eur Heart J 2022; n = 512): Japanese multicentre registry showing a high long-term arrhythmic risk (estimated 10-year fatal ventricular arrhythmia rate ~32 percent, composite of death, HF hospitalization or fatal arrhythmia ~48 percent), supporting the principle that PET guides immunosuppression while CMR LGE and LVEF guide ICD implantation.
- CHASM-CS-RCT (Birnie et al., Ongoing Randomized Trial): Compares low-dose Prednisone + Methotrexate with standard-dose Prednisone monotherapy in newly diagnosed active CS, testing whether early steroid-sparing therapy is non-inferior with less corticosteroid toxicity; results are awaited.
Key references
- Birnie DH, Sauer WH, Bogun F, et al.: HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis, Heart Rhythm, 2014.
- Cheng RK, Kittleson MM, Beavers CJ, et al.: Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association, Circulation, 2024.
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al.: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, European Heart Journal, 2022.
- Nabeta T, Kitai T, Naruse Y, et al. (ILLUMINATE-CS Investigators): Risk stratification of patients with cardiac sarcoidosis: the ILLUMINATE-CS registry, European Heart Journal, 2022.
meritmedscript.comDr. Sidhartha Mullapudi
